

PUBBLICAZIONI PER ESTESO

- 1) L Pace, P Perrone-Filardi, P Mainenti, A Cuocolo, P Vezzuto, M Prastaro, A Varrone, **G De Luca**, A Soricelli, S Betocchi, M Chiariello and M Salvatore.
Identification of viable myocardium in patients with cronic coronary artery disease using rest-redistribution Thallium-201 tomography: optimal image analisys.
J Nucl Med 1998; 39; 1869-1874.

- 2) C Capozzolo, F Piscione, **G De Luca**, A Cioppa, P Mazzarotto, D Leosco, P Golino, C Indolfi, M Chiariello.
Direct coronary stenting: Effects on coronary blood flow, immediate and late clinical outcome.
Catheterization and Cardiovascular Intervention 2001; 53: 464-473.

- 3) F Piscione, P Perrone-Filardi, **G De Luca**, M Prastaro, C Indolfi, P Golino, S Dellegrottaglie, M Chiariello.
Low-dose dobutamine echocardiography predicting functional recovery after coronary revascularization.
Heart 2001; 86: 679-86.

- 4) S. Dellegrottaglie, P Perrone-Filardi, L Pace, M Prastaro, MP Ponticelli, AM Della Morte, F Piscione, G Storto, **G De Luca**, M Salvatore, M Chiariello.
Prediction of log-term effetes of revascularization on regional and global left ventricular function by dobutamine echocardiography and rest Tl-201 imaging alone and in combination in patients with chronic coronary artery disease.
J NuclCardiol 2002; 9:174-82.

- 5) F Piscione, **G. De Luca**, P Perrone-Filardi, M. Prastaro, L. Pace, G. Galasso, G. Marrazzo, M, Salvatore, M, Chiariello.
Relation between contractile reserve, 201-Tl uptake and collateral circulation in collateral-dependent myocardium. Implications regarding the evaluation of myocardial viabilty.
J NuclCardiol 2003;10: 17-27.

- 6) **G De Luca**, H Suryapranata, K Thomas, AWJ van 't Hof, MJ de Boer, JCA Hoorntje, F Zijlstra.
Outcome In Patients Treated With Primary Angioplasty For Acute Myocardial Infarct Due To Left Main Coronary Artery Occlusion.
American Journal of Cardiology 2003; 91: 235-8.

Giuseppe De Luca, MD, PhD

- 7) **G De Luca**, H Suryapranata, F Zijlstra, AWJ van't Hof, JCA Hoorntje, ATM Gosselink, JH Dambrink, and MJ de Boer, on behalf of the ZWOLLE Myocardial Infarction Study Group.

Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty.

J Am Coll Cardiol 2003; 423: 991-7.

- 8) **G De Luca**, N Ernst, F Zijlstra, AWJ van't Hof, JCA Hoorntje, JHE Dambrink, ATM Gosselink, MJ de Boer, H Suryapranata.

Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty.

J Am Coll Cardiol 2004; 43: 1363-7.

- 9) **G De Luca**, AWJ van't Hof, MJ de Boer, JCA Hoorntje, ATM Gosselink, JHE Dambrink, JP Ottervanger, F Zijlstra and H Suryapranata.

Impaired myocardial perfusion is a major explanation of the poor outcome observed in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction and signs of heart failure.

Circulation 2004; 109: 958-61.

- 10) **G De Luca**, H Suryapranata, AWJ van't Hof, JCA Hoorntje, JHE Dambrink, ATM Gosselink, MJ de Boer, F Zijlstra and on behalf of the ZWOLLE Myocardial Infarction Study Group.

Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: Implications for early discharge.

Circulation 2004; 109: 2737-43.

- 11) **G De Luca**, H Suryapranata, JP Ottervanger, and EM Antman.

Time-delay to Treatment and Mortality in Primary Angioplasty for Acute Myocardial Infarction: Every minute delay counts.

Circulation 2004; 109; 1223-5.

- 12) **G De Luca**, AWJ van't Hof, MJ de Boer, JP Ottervanger, JCA Hoorntje, ATM Gosselink, JHE Dambrink, F Zijlstra, and H Suryapranata.

Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty.

Eur Heart Journal 2004; 25: 1009-13

13) H Lange, H Suryapranata, **G De Luca**, C Börner J Dille, K Kallmayer, MN Pasalary, E Scherer MD, JH Dambrink.
A Clinical Trial of Folate Therapy and in-Stent Restenosis after coronary stenting.
New England Journal of Medicine 2004; 350: 2673-81.

14) **G De Luca**, H Suryapranata, AWJ van't Hof, JP Ottervanger, JCA Hoorntje, ATM Gosselink, JHE Dambrink, F Zijlstra, and MJ de Boer.
Comparison between ticlopidine and clopidogrel in patients with ST-segment elevation myocardial infarction treated with coronary stenting.
ThrombHaemost 2004; 91 1084-9.

15) **G De Luca**, H Suryapranata, JHE Dambrink, JP Ottervanger, AWJ van't Hof, F Zijlstra, JCA Hoorntje, ATM Gosselink, and MJ de Boer.
Sex-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty. Data from the Zwolle Myocardial Infarction Study
Am Heart J 2004; 148: 852-6.

16) **G De Luca**, H Suryapranata, F Zijlstra, JP Ottervanger, AWJ van't Hof, JCA Hoorntje, ATM Gosselink, JHE Dambrink, MJ de Boer.
Statin therapy and mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty.
Neth Heart J 2004; 12: 271-8.

17) H Suryapranata, **G De Luca**, F Zijlstra, AWJ van't Hof, JP Ottervanger, JCA Hoorntje, JHE Dambrink, ATM Gosselink, and MJ de Boer.
Routine stenting for acute myocardial infarction: a randomized trial in unselected patients.
Heart 2005; 91: 641-5.

18) **G De Luca**, A C Maas, AWJ van't Hof, JP Ottervanger, JCA Hoorntje, ATM Gosselink, JHE Dambrink, MJ de Boer, and H Suryapranata.
ST-segment depression resolution and mortality after successful mechanical reperfusion in patients with ST-segment elevation myocardial infarction.
Am J Cardiol. 2005; 95: 234-6..

19) **G De Luca**, AWJ van t'Hof, JP Ottervanger, JCA Hoorntje, AT Marcel Gosslink, JHE Dambrink, F Zijlstra, MJ de Boer, H Suryapranata.

Aging, impaired myocardial perfusion and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty.

Eur Heart Journal 2005; 26: 662-6.

20) **G De Luca**, H Suryapranata, GW Stone, D Antoniucci, JE Tcheng, FJ Neumann, F Van de Werf, EM Antman, and EJ Topol.

Adjunctive abciximab to reperfusion therapy in patients with acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.

JAMA 2005; 193: 1759-65

21) Piscione F, Galasso G, **De Luca G**, Marrazzo G, Sarno G, Viola O, Accardo D, Chiariello M.

Late reopening of an occluded infarct related artery improves left ventricular function and long term clinical outcome.

Heart. 2005; 91: 646-51.

22) **De Luca G**, Smit JJ, Ernst N, Suryapranata H, Ottervanger JP, Hoorntje JC, Dambrink JH, Gosslink AT, de Boer MJ, van't Hof AW.

Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction.

ThrombHaemost. 2005; 93: 820-3.

23) Barbato E, Piscione F, Bartunek J, Galasso G, Cirillo P, **De Luca G**, Iaccarino G, De Bruyne B, Chiariello M, Wijns W.

Role of beta2 adrenergic receptors in human atherosclerotic coronary arteries.

Circulation 2005; 111: 288-94.

24) **De Luca G**, Ernst N, Suryapranata H, Ottervanger JP, Hoorntje JC, Gosslink AT, Dambrink JH, de Boer MJ, van't Hof AW.

Relation of interhospital delay and mortality in patients with ST-segment elevation myocardial infarction transferred for primary coronary angioplasty.

Am J Cardiol. 2005 Jun 1;95(11):1361-3.

25) Timmer JR, van der Horst IC, **De Luca G**, Ottervanger JP, Hoorntje JC, de Boer MJ, Suryapranata H, Dambrink JH, Gosselink M, Zijlstra F, van 't Hof AW; Zwolle Myocardial Infarction Study Group.

Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus.

Am J Cardiol 2005 95: 1375-7.

26) **De Luca G**, Suryapranata H, Ottervanger JP, van't Hof AW, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ.

Absence of seasonal variation in myocardial perfusion, enzymatic infarct size, and mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty.

Am J Cardiol 2005; 95: 1459-61.

27) van der Horst IC, **De Luca G**, Ottervanger JP, de Boer MJ, Hoorntje JC, Suryapranata H, Dambrink JH, Gosselink AT, Zijlstra F, van 't Hof AW.

ST-segment elevation resolution and outcome in patients treated with primary angioplasty and glucose-insulin-potassium infusion.

Am Heart J 2005; 149: 1135.

28) **De Luca G**, Suryapranata H, Grimaldi R, Chiariello M.

Coronary stenting and abciximab in primary angioplasty for ST-segment-elevation myocardial infarction.

QJM. 2005; 6: 874-80.

29) **De Luca G**, Suryapranata H, de Boer MJ.

The Zwolle global experience on primary percutaneous coronary intervention.

Ital Heart J 2005; 6: 453-8.

30) **G De Luca**, H Suryapranata, JP Ottervanger, AWJ van't Hof, JCA Hoorntje, ATM Gosselink, JHE Dambrink, JPS Henriques, F Zijlstra, MJ de Boer.

Circadian variation in myocardial perfusion and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty.

Am Heart J 2005; 150: 1185-9.

Giuseppe De Luca, MD, PhD

31)G De Luca, N Ernst, H Suryapranata JP Ottervanger, JCA Hoorntje, ATM Gosselink, JHE Dambrink, F Zijlstra, MJ de Boer, and Arnoud WJ van't Hof.
Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction.
Am Heart J 2006; 151: 1256-9.

32)G De Luca, MJ de Boer, JP Ottervanger, AWJ van't Hof, JCA Hoorntje, ATM Gosselink, JHE Dambrink, H Suryapranata.
Impact of beta-blocker and statin therapy at discharge on long-term mortality after primary angioplasty for ST-segment elevation myocardial infarction.
Am J Cardiology 2005; 96: 806-9.

33)De Luca G, Suryapranata H, Gregorio G, Lange H, Chiariello M.
Homocysteine and its effects on in-stent restenosis.
*Circulation*2005; 112: e307-11.

34)G De Luca, AC Maas, H Suryapranata, JP Ottervanger, JCA Hoorntje, ATM Gosselink, JHE Dambrink, MJ de Boer, and AWJ van't Hof.
Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-segment elevation myocardial infarction.
Am Heart J. 2005; 150: 1248-54.

35)G De Luca, AWJ van't Hof, JP Ottervanger, JCA Hoorntje, ATM Gosselink, JHE Dambrink, F Zijlstra, MJ de Boer, and H Suryapranata..
Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty.
Am Heart J 2005; 150: 557-62

36)De Luca G, Grimaldi R, Kockman W, Suryapranata H.
Current role of primary angioplasty for acute myocardial infarction.
ASEAN Heart Journal 2003; 10: 36-43.

37) Timmer JR, van der Horst IC, Ottervanger JP, **De Luca G**, van't Hof AW, Bilo HJ, Zijlstra F.

Glucose-insulin-potassium infusion as adjunctive therapy in myocardial infarction: current evidence and potential mechanisms.

Ital Heart J 2004; 5: 727-31.

38) **De Luca G**, Suryapranata H and Chiariello M.

Tenecteplase followed by immediate angioplasty is more effective than tenecteplase alone for people with STEMI.

Evid Based Cardiovasc Med 2005; 9: 284-7.

39) **De Luca G**, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Bonizzoni E, Topol EJ, Chiariello M

Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials.

J Am Coll Cardiol 2006; 47: 685-6.

40) **De Luca G**, Ernst N, van't Hof AW, Ottervanger JP, Hoorntje JC, Dambrink JH, Gosslink AT, de Boer MJ, Suryapranata H.

Preprocedural Thrombolysis in Myocardial Infarction (TIMI) flow significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute anterior myocardial infarction treated by primary angioplasty.

Am Heart J 2005; 150: 827-31.

41) **De Luca G**, Suryapranata H, Piscione F, Barbato E, Chiariello M.

Stenting and abciximab in primary angioplasty: a review of current status.

Ital Heart J. 2005; 6: 874-80.

42) Barbato E, De Bruyne B, MacCarthy P, Pijls NH, **De Luca G**, Volpe M.

Functional assessment of coronary atherosclerosis in the catheterization laboratory: the key role of fractional flow reserve.

Ital Heart J 2005; 6: 549-56.

43) De Luca G, Suryapranata H, van't Hof AWJ, Ottervanger JP, Hoorntje, Dambrink JHE, Gosselink ATM, and de Boer MJ.

Impact of routine stenting on myocardial perfusion and the extent of myocardial necrosis in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction.

Am Heart J. 2006; 151: 1296.e1-6.

44) De Luca G, Suryapranata H, Timmer J, Ottervanger JP, van't Hof AWJ, Hoorntje JCA, Dambrink JHE, Gosselink ATM, and de Boer MJ.

Impact of routine stenting on clinical outcome in diabetic patients undergoing primary angioplasty for ST-segment elevation myocardial infarction.

Diabetes Care 2006; 29: 920-3.

45) De Luca G, Suryapranata H, Chiariello M.

Aspiration thrombectomy and Primary PCI.

Heart 2006; 92: 867-869.

46) De Luca G, Suryapranata H, Ottervanger JP, van't Hof AWJ, Hoorntje JCA, Gosselink ATM, Dambrink JHE, de Boer MJ.

Impact of statin therapy at discharge on 1-year mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty.

Atherosclerosis. 2006; 189: 186-92.

47) Breeman A, Ottervanger JP, Boersma E, De Luca G.

Coronary revascularisation for Non-ST Elevation Acute Coronary Syndrome. State of the art.

Journal of Cardiovascular Medicine 2006; 7: 108-13.

48) De Luca G, Suryapranata H, Ottervanger JP, van't Hof AWJ, Hoorntje JCA, Dambrink JH, Gosselink ATM and de Boer MJ.

Comparison between stenting and balloon in elderly patients undergoing primary angioplasty for ST-segment elevation myocardial infarction.

Int J Cardiol 2007; 119: 306-9.

49) **De Luca G**, Suryapranata H, de Boer MJ, Ottervanger JP, Hoorntje JCA, Gosselink ATM, Dambrink JH, Ernst N, and van't Hof AWJ.

Combination between electrocardiographic and angiographic markers of reperfusion in the prediction of infarct size in patients with ST-segment elevation myocardial infarction undergoing successful primary angioplasty.

Int J Cardiol 2007; 117: 232-7.

50) **De Luca G**, Suryapranata H, van't Hof AWJ, Ottervanger JP, Hoorntje JCA, , Dambrink JH, Gosselink ATM and de Boer MJ.

Comparison between stenting and balloon angioplasty in patients undergoing primary angioplasty of small coronary vessels.

Am Heart J 2006; 152: 915-20.

51) **De Luca G**, Suryapranata H, Chairiello M.

Prevention of distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: a review of current status.

ThrombHaemost. 2006 Dec;96(6):700-10

52) **De Luca G**, Suryapranata H, Stone GW, Antoniucci D, Neumann FJ, Chiariello M.

Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: a meta-analysis of randomized trials.

American Heart Journal 2007; 153: 343-53.

53) Dudek D, Rakowski T, El Massri N, Sorysz D, Zalewski J, Legutko J, Dziewierz A, Rzeszutko L, Zmudka K, Piwowarska W, **De Luca G**, Kaluza GL, Janion M, Dubiel JS.

Patency of infarct related artery after pharmacological reperfusion during transfer to primary percutaneous coronary intervention influences left ventricular function and one-year clinical outcome.

Int J Cardiol 2008; 124: 326-31

54) **De Luca G**, Suryapranata H, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Van't Hof AW.

Postprocedural single-lead ST-segment deviation and long-term mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty.

Heart 2008; 94: 44-7.

- 55) De Luca G**, Suryapranata H, Stone GW, Antoniucci D, Biondi-Zoccai G, Kastrati A, Chiariello M, Marino P.
Coronary stenting versus balloon angioplasty for acute myocardial infarction: A meta-regression analysis of randomized trials.
Int J Cardiol 2008; 126: 37-44.
- 56) De Rosa S**, Cirillo P, **De Luca G**, Galasso G, Esposito G, Leosco D, Piscione F, Chiariello M.
Rheolytic thrombectomy during percutaneous coronary intervention improves long-term outcome in high-risk patients with acute myocardial infarction.
J IntervCardiol. 2007; 20: 292-8.
- 57) Citro R**, D'Andrea A, Patella MM, Ducceschi V, Provenza G, **De Luca G**, Calabro R, Gregorio G.
Prognostic value of tissue Doppler-derived ventricular asynchrony in patients with left bundle branch block but not advanced heart failure.
J Cardiovasc Med (Hagerstown) 2007; 8: 568-74
- 58) De Luca G**, Carbone G, Maione A, Gregorio G.
In-stent thrombosis after discontinuation of antiplatelet therapy 2 years after DES implantation: a case report.
Int J Cardiol. 2007 Apr 4;116(3):399-400.
- 59) De Luca G**, Suryapranata H, de Boer MJ, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, Van't Hof AW.
Impact of vessel size on distal embolization, myocardial perfusion and clinical outcome in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction.
J Thromb Thrombolysis 2009; 27: 198-203.
- 60) De Luca G**, Marino P.
Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
Am Heart J 2007; 154: 1085.e1-6.

61) Biondi-Zoccai G, Moretti C, Abbate A, Lipinski M, **De Luca G**, Agostoni P, Meliga E, Goudreau E, Vetrovec G, Trevi GP, Sheiban I.

Percutaneous coronary stenting in patients with left ventricular systolic dysfunction: a systemic review and meta-analysis.

Eurointerv 2007; 3: 1-7.

62) **De Luca G.**

Overview of contemporary reperfusion strategies in acute ST-elevation myocardial infarction.

Cardiology International; Autumn 2007: 92-97.

De Luca G, Suryapranata H, Marino P.

Primary angioplasty vs thrombolysis.

Indian Heart J 2007; 59: 123-131.

63) **De Luca G**, Marino P.

Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials. Am Heart J. 2007 Dec;154(6):1085.e1-6.

64) Ferrara LA, Guida L, Ferrara F, **De Luca G**, Staiano L, Celentano A, Mancini M
Cardiac structure and function and arterial circulation in hypertensive patients with and without metabolic syndrome

J Hum Hypertens 2007; 21(9):729-35

65) **De Luca G**, Stone GW, Suryapranata H, Laarman GJ, Menichelli M, Kaiser C, Valgimigli M, Di Lorenzo E, Dirksen MT, Spaulding C, Pittl U, Violini R, Percoco G, Marino P.

Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.

Int J Cardiol 2009; 133: 213-22.

- 66) **De Luca G**, Gibson M, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U, Dudek D, Arntz HR, Zorman S, Gabriel M, Emre A, Cutlip D, Biondi-Zoccai G, Rakowski T, Gyongyosi M, Marino P, Huber K, Van't Hof A
Early Glycoprotein IIb-IIIa inhibitors in Primary angioplasty (EGYPT) cooperation. An individual patients' data meta-analysis.
Heart 2008; 94: 1548-58.
- 67) **De Luca G**, Suryapranata H, Marino P.
Reperfusion strategies in acute ST-elevation myocardial infarction: an overview of current status.
Prog Cardiovasc Dis. 2008 Mar-Apr;50(5):352-82.
- 68) **De Luca G**, Savonitto S, Greco C, Parodi G, Dajelli Ermolli NC, Silva C, Lucci D, Ronzini L, Maggioni AP, Cuccia C.
Cardiogenic shock developing in the Coronary Care Unit in patients with ST-elevation myocardial infarction.
J CardiovascMed2008; 9: 1023-9.
- 69) **De Luca G**, Cassetti E, Marino P
Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials.
JThromb Thrombolysis. 2009 May;27(4):365-78.
- 70) **De Luca G**, Marino P.
PCI-related time delay, patient's risk profile and survival benefits of primary angioplasty vs lytic therapy in STEMI.
Am J Emer Med 2009; 27: 712-9.
- 71) **De Luca G**, Marino P. **Facilitated PCI with combotherapy among STEMI patients. A meta-analysis of randomized trials.** Am J Emer Med 2009; 27: 683-90

72)De Luca G, Marino P.
Advances in antithrombotic therapy as adjunct to reperfusion therapies for ST-segment elevation myocardial infarction.
Thrombosis and Haemostasis 2008; 100: 184-95.

73)De Luca G, Marino P.
Antithrombotic therapies in primary angioplasty:rationale, results and future directions.
Drugs 2008; 68: 2325-44

74)De Luca G, Suryapranata H, van't Hof AWJ, Ottervanger JP, Hoorntje JCA, Dambrink JHE, AT Gosselink ATM, de Boer MJ.
Routine stenting vs balloon angioplasty in ST-segment elevation myocardial infarction due to proximal left anterior descending coronary artery occlusion.
J Cardiovasc Med (Hagerstown). 2009 Jan;10(1):22-6.

75)De Luca G.
Adjunctive antithrombotic therapy during Primary PCI.
Eur Heart J Supplement 2008; 10 (supplement J) :J2-J14.

76)De Luca G,Dudek D, Sardella G, et al. **Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary PCI for ST-elevation myocardial infarction: a meta-analysis of randomized trials.**
Eur Heart J. 2008 Dec;29(24):3002-10.

77)De Luca G, Biondi-Zoccai G and Marino P.
Transferring patients with ST-segment elevation myocardial infarction for mechanical reperfusion: A meta-regression analysis of randomized trials.
Annals of Emergency Medicine 2008; 52: 665-76

78)De Luca G, Cassetti E, Marino PN, Melandri G, Di Mario C.
The CARESS-in-AMI trial
G Ital Cardiol 2008; 9: 585-92.

79) **De Luca G**, Michael Gibson C, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U, Dudek D, Arntz HR, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Huber K, Van't Hof AW

Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation.

J Thromb Thrombolysis 2009; 28: 288-98.

80) Dudek D, Dziewierz A, Siudak Z, Rakowski T, Zalewski J, Legutko J, Mielecki W, Janion M, Bartus S, Kuta M, Rzeszutko L, **De Luca G**, Zmudka K, Dubiel JS.

Transportation with very long transfer delays (>90 min) for facilitated PCI with reduced-dose fibrinolysis in patients with ST-segment elevation myocardial infarction The Krakow Network.

Int J Cardiol. 2008 ;39(3):218-27

81) **De Luca G**, Valgimigli M, Spaulding C, Menichelli M, Rocca HP, van derHoeven BL, Di Lorenzo E, de la Llera LS, Pasceri V, Pittl U, Percoco G, Violini R, Stone GW.

Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JThromb Thrombolysis 2009; 28: 200-10.

82) **De Luca G**.

delayed is treatment denied!

EspCardiol 2009; 62: 1-6.

Treatment

Rev

83) **De Luca G**, Santagostino M, Secco GG, Cassetti E, Giuliani L, Franchi E, Coppo L, Iorio S, Venegoni L, Rondano E, Dell'Era G, Rizzo C, Pergolini P, Monaco F, Bellomo G, Marino P, on behalf of the Novara Atherosclerosis Study Group (NAS).

Mean platelet volume and the extent of coronary artery disease: results from a large prospective study.

Atherosclerosis 2009; 206: 292-7.

- 84) **De Luca G**, Ucci G, and Marino P.
Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty. A meta-regression analysis of randomized trials.
Eur Heart J 2009; 30: 2705-13.
- 85) **De Luca G**, Ucci G, Cassetti E, and Marino P. **Benefits from Abciximab administration as compared to small molecules among patients with ST-segment elevation myocardial infarction treated with primary angioplasty. A meta-analysis of randomized trials.**
J Am Coll Cardiol 2009; 53: 1668-73
- 86) Di Lorenzo E, **De Luca G**, Sauro R, Varricchio A, Papasso M, Lanzillo T, Manganelli F, Martello C, Siano F, Pagliuca MR, Stanco G, Rosato G
The PaclitAxel or Sirolimus-Eluting Stent vs Bare Metal Stent in primary angioplasty (PASEO) randomized trial.
JACC Cardiovasc Interv 2009; 2: 515-23
- 87) Di Lorenzo E, Sauro R, Varricchio A, Papasso M, Lanzillo T, Manganelli F, Martello C, Siano F, Pagliuca MR, Stanco G, Rosato G, **De Luca G**.
Long-term benefits of drug-eluting stents as compared to BMS in STEMI. The PaclitAxel or Sirolimus-Eluting Stent vs Bare Metal Stent in primary angioplasty (PASEO) randomized trial.
Am Heart J 2009; 158: e43-50.
- 88) Juwana BY, Suryapranata H, Ottervanger JP, **De Luca G**, van't Hof AWJ, Dambrink JHE, de Boer MJ, Gosselink ATM, Hoorntje JCA. **Comparison of Rapamycin- and Paclitaxel-Eluting Stents in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.**
Am J Cardiol 2009; 104: 205-9.

- 89) **De Luca G**, Gibson CM, Bellandi F, Noc M, Dudek D, Zeymer U, Arntz HR, Cutlip D, Maioli M, Zorman S, Mesquita Gabriel H, Emre A, Rakowski T, Gyongyosi M, Huber K, Van'tHof AW.
Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors.
Atherosclerosis 2009; 207: 181-5.
- 90) Ribichini F, Tomai F, **De Luca G**, Boccuzzi G, Presbitero P, Pesarini G, Ferrero V, Ghini AS, Pastori F, De Luca L, Zavalloni D, Soregaroli D, Garbo R, Franchi E, Marino P, Minelli M, Vassanelli C. **A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.** J Cardiovasc Med (Hagerstown) 2009; 10: 192-9.
- 91) **De Luca G**, Cassetti E, Verdoia M, Marino P. **Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty. A meta-analysis of randomized trials.** Thrombosis and Haemostasis 2009; 102: 428-36.
- 92) **De Luca G**, Gibson CM, Huber K, Zeymer U, Dudek D, Cutlip D, Bellandi F, Noc M, Emre A, Zorman S, Gabriel HM, Maioli M, Rakowski T, Gyöngyösi G, van't Hof AWJ. **Association between advanced Killip class at presentation and impaired myocardial perfusion among STEMI Patients treated with Primary Angioplasty and adjunctive glycoprotein IIb-IIIa inhibitors.** Am Heart J 2009; 158: 416-21.
- 93) Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, **De Luca G**
Long-term results of drug-eluting stents as compared to BMS in STEMI. The PaclitAxel or Sirolimus-Eluting Stent vs Bare Metal Stent in primary angioplasty (PASEO) randomized trial
Circulation 2009; 120: 964-72

- 94) Franchi E, Marino P, Biondi-Zoccai GG, **De Luca G**, Vassanelli C, Agostoni P.
Transradial versus transfemoral approach for percutaneous coronary procedures.
CurrCardiol Rep 2009; 11: 391-7.
- 95) **De Luca G**, Gibson CM, Bellandi F, Noc M, Maioli M, Zorman S, Zeymer U, Gabriel HM, Emre A, Cutlip D, Arntz H-R, Dudek D, Rakowski T, Gyongyosi M, Huber K, van'tHof AWJ
Impact of distal embolization on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors. Insights from the EGYPT cooperation.
J Thromb Thrombolysis. 2009;30(1):23-8
- 96) **De Luca G**, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, Di Lorenzo E.
Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors and BMS or DES
J Thromb Thrombolysis. 2010 (e2009); 30(2):133-41
- 97) **De Luca G**, Małek LA, Maciejewski P, Wasek W, Niewada M, Kamiński B, Drzewiecki J, Kośmider M, Kubica J, Rużyłło W, Peruga JZ, Dudek D, Opolski G, Dobrzycki S, Gil RJ, Witkowski A; STEMI 2003 Registry Collaborators.
Impact of diabetes on survival in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: insights from the POLISH STEMI registry. Atherosclerosis. 2010 Jun;210(2):516-20.
- 98) Navarese EP, Lupi A, Buffon A, **De Luca G**. **Meta-analysis of ablation of atrial flutter and supraventricular tachycardia.** Am J Cardiol. 2010 Mar 1;105(5):758..
- 99) Pesarini G, Amoruso A, Ferrero V, Bardelli C, Fresu LG, Perobelli L, Scappini P, **De Luca G**, Brunelleschi S, Vassanelli C, Ribichini F. **Cytokines release inhibition from activated monocytes, and reduction of in-stent neointimal growth in humans.** Atherosclerosis 2010; 211: 242-8.

- 100) **De Luca G**, Gibson CM, Gyöngyösi M, Zeymer U, Dudek D, Arntz HR, Bellandi F, Maioli M, Noc M, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Huber K, Van't Hof AW.
Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation.
J Thromb Thrombolysis. 2010;30(3):342-6
- 101) Rondano E, Dell'Era G, **De Luca G**, Piccinino C, Bellomo G, Marino PN.
Left atrial asynchrony is a major predictor of 1-year recurrence of atrial fibrillation after electrical cardioversion.
J Cardiovasc Med (Hagerstown). 2010 Jul;11(7):499-506
- 102) **De Luca G**, Parodi G, Antoniucci D.
Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis.
J Thromb Thrombolysis. 2010;30(4):452-8
- 103) De Luca L, Tomai F, Verdoia M, **De Luca G**. **Evaluation and management of special subgroups after primary percutaneous coronary intervention.** Am Heart J. 2010 Dec;160(6 Suppl):S22-7.
- 104) **De Luca G**, Secco GG, Santagostino M, Venegoni L, Iorio S, Casseti E, Verdoia M, Coppo L, Di Mario C, Bellomo G, Marino P; on behalf of the Novara Atherosclerosis Study Group (NAS). **Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study.** NutrMetab Cardiovasc Dis. 2012 (e2010);22(5):426-33
- 105) Navarese EP, De Servi S, Buffon A, Suryapranata H, **De Luca G**.
Clinical impact of simultaneous complete revascularization vs. culprit only primary angioplasty in patients with st-elevation myocardial infarction and multivessel disease: a meta-analysis. JThromb Thrombolysis 2011; 31: 217-25.

- 106) **De Luca G**, Venegoni L, Iorio S, Secco GG, Cassetti E, Verdoia M, Schaffer A, Coppo L, Bellomo G, Marino P; Novara Atherosclerosis Study Group. **Platelet distribution width and the extent of coronary artery disease: results from a large prospective study.** Platelets 2010; 21: 508-14.
- 107) **De Luca G**, Santagostino M, Secco GG, Cassetti E, Giuliani L, Coppo L, Schaffer A, Fundaliotis A, Iorio S, Venegoni L, Bellomo G, Marino P. **Platelet-Large Cell Ratio and the extent of coronary artery disease: results from a large prospective study.** J Thromb Thrombolysis 2010; 30: 426-33.
- 108) **De Luca G**, Verdoia M, Cassetti E, Schaffer A, Cavallino C, Bolzani V, Marino P; Novara Atherosclerosis Study Group (NAS). **High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population.** J Thromb Thrombolysis 2010;31(4):458-63
- 109) Parodi G, **De Luca G**, Moschi G, Bellandi B, Valenti R, Migliorini A, Carrabba N, Antonucci D. **Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy.** J Thromb Thrombolysis. 2010 Nov;30(4):446-51.
- 110) Mangiacapra F, Wijns W, **De Luca G**, Muller O, Trana C, Ntalianis A, Heyndrickx G, Vanderheyden M, Bartunek J, De Bruyne B, Barbato E. **Thrombus aspiration in primary percutaneous coronary intervention in high-risk patients with ST-elevation myocardial infarction: a real-world registry.** Catheter Cardiovasc Interv 2010; 76: 70-6.

- 111) **De Luca G**, Verdoia M, Cassetti E. **Thrombectomy during primary angioplasty: methods, devices, and clinical trial data.** CurrCardiol Rep 2010; 12: 422-8.
- 112) **De Luca G**, Navarese EP, Cassetti E, Verdoia M, Suryapranata H. **Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy.** Am J Cardiol 2011; 107: 198-203.
- 113) Secco GG, Marino PN, Carriero A, **De Luca G**. **Silent double aortic arch coincidentally found during cardiac catheterization in elderly man.** Congenital Heart Dis. 2011 Jan;6(1):74-6.
- 114) Navarese EP, De Servi S, Michael Gibson C, Buffon A, Castriota F, Kubica J, Petronio AS, Andreotti F, **De Luca G**. **Early vs. delayed invasive strategy in patients with acute coronary syndromes without ST-segment elevation: a meta-analysis of randomized studies.** QJM. 2011; 104: 193-200.
- 115) Secco GG, Bortnik M, Occhetta E, Dell'Era G, Merlo E, **De Luca G**, Marino PN. **An unusual case of ECG ST-segment elevation.** J Cardiovasc Med (Hagerstown). 2012 (e2011); 13(4):289-91
- 116) Navarese EP, Verdoia M, Schaffer A, Suriano P, Kozinski M, Castriota F, De Servi S, Kubica J, **De Luca G**. **Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.** QJM 2011;104(7):561-9

- 117) Ribichini F, Tomai F, **De Luca G**, Boccuzzi G, Presbitero P, Pesarini G, Ferrero V, Ghini AS, Abukaresh R, Aurigemma C, De Luca L, Zavalloni D, Soregaroli D, Marino P, Garbo R, Zanolla L, Vassanelli C; CEREAS-DES investigators. **Immunosuppressive Therapy with Oral Prednisone to Prevent Restenosis after PCI. A Multicenter Randomized Trial.** Am J Med 2011; 124: 434-43.
- 118) Secco GG, Marino PN, Venegoni L, **De Luca G**. **Percutaneous Revascularization of Chronic Total Occlusion of the Left Main Coronary Artery.** Rev EspCardiol 2011; 64: 431-433.
- 119) Navarese EP, **De Luca G**, Castriota F, Kozinski M, Gurbel P, Gibson CM, Andreotti F, Buffon A, Siller-Matula JM, Sukiennik A, De Servi S, Kubica J. **Low-Molecular-Weight Heparins vs Unfractionated Heparin in the Setting of Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction: a Meta-analysis.** J ThrombHaemost. 2011;9(10):1902-15
- 120) Cassese S, **De Luca G**, Villari B, Berti S, Bellone P, Alfieri A, Montinaro A, Quaranta G, Marraccini P, Piscione F; on behalf of MATRIX Study Investigators. **Reduced antiplatelet therapy after drug-eluting stenting: Multicenter Janus Flex Carbostent implantation with short dual antiplatelet treatment - two or six months. MATRIX Study.** Catheter Cardiovasc Interv. 2012 (e2011); 80(3):408-16
- 121) **De Luca G**, Bellandi F, Huber K, Noc M, Petronio AS, Arntz HR, Maioli M, Gabriel HM, Zorman S, De Carlo M, Rakowski T, Gyongyosi M, Dudek D. **Early Glycoprotein IIb-IIIa Inhibitors in Primary Angioplasty- Abciximab**

Long-Term Results (EGYPT-ALT) Cooperation. An Individual Patients' Data Meta-Analysis. J
ThrombHaemost. 2011;9(12):2361-70

- 122) De Luca G.
GlycoproteinIIb-IIIaInhibitors.
CardiovascTher. 2012 (e2011); 30(5):e242-54
- 123) Navarese EP, Kozinski M, Obonska K, Margheri M, Gurbel PA, Kubica J, De Luca G.
Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: A meta-analysis of randomized trials.
Platelets. 2012 (e2011); 23(4):274-81
- 124) De Luca G, Iorio S, Venegoni L, Marino P.
Evaluation of Intracoronary Adenosine to Prevent Periprocedural Myonecrosis in Elective Percutaneous Coronary Intervention (From the PREVENT-ICARUS Trial). Am J
Cardiol. 2012 (e2011); 109(2):202-71
- 125) De Luca G, Venegoni L, Iorio S, Giuliani L, Marino P. **Effects of increasing doses of intracoronary adenosine on the assessment of fractional flow reserve.** JACC Cardiovasc
Interv 2011; 4: 1079-84.
- 126) Secco GG, Foin N, Viceconte N, Borgia F, De Luca G, Di Mario C.
Optical coherence tomography for guidance of treatment of in-stent restenosis with cutting balloons.
EuroIntervention. 2011;7(7):828-34.

Giuseppe De Luca, MD, PhD

- 127) Navarese EP, Kubica J, Castriota F, Gibson CM, **De Luca G**, Buffon A, Bolognese L, Margheri M, Andreotti F, Di Mario C, De Servi S. **Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials.** EuroIntervention. 2011;7(8):985-94
- 128) **De Luca G**, Navarase E, Suryapranata H. **A meta-analytic overview of thrombectomy during primary angioplasty.** Int J Cardiol. 2013; 166(3):606-12
- 129) Vrizz O, Minisini R, Citro R, Guerra V, Zito C, **De Luca G**, Pavan D, Pirisi M, Limongelli G, Bossone E. **Analysis of beta1 and beta2-adrenergic receptors polymorphism in patients with apical ballooning cardiomyopathy.** Acta Cardiol. 2011;66(6):787-90
- 130) **De Luca G**, Verdoia M, Binda G, Schaffer A, Suryapranata H, Marino P. **Aspirin desensitization in patients undergoing planned or urgent coronary stent implantation. A single-center experience.** Int J Cardiol. 2013 (e2012); 167(2):561-3
- 131) **De Luca G**, Brener SJ, Mehran R, Lansky AJ, McLaurin BT, Cox DA, Cristea E, Fahy M, Stone GW. **Implications of pre-procedural TIMI flow in patients with non ST-segment elevation acute coronary syndromes undergoing percutaneous coronary revascularization: Insights from the ACUTY trial.** Int J Cardiol. 2013 (e2012);167(3):727-32
- 132) Klomp M, Damman P, Beijk MA, Tan KH, Balian V, **De Luca G**, Tijssen JG, Silber S, de Winter RJ; on behalf of the e-HEALING investigators. **Differences in cardiovascular risk factors and clinical outcomes between**

Western European and Southeast Asian patients treated with the Genous Bio-engineered R stent: an e-HEALING worldwide registry substudy. *Coron Artery Dis* 2012;23: 271-7

- 133) **De Luca G**, Verdoia M, Suryapranata H.
Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: A meta-analysis of 8 randomized trials. *Atherosclerosis.* 2012;222: 426-33
- 134) **De Luca G**, Dirksen MT, Spaulding C, Kelbaek H, Schlij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Díaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Cortese G, Suryapranata H, Stone GW; Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation. **Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials.** *Arch Intern Med.* 2012;172: 611-21
- 135) De Luca G, Parodi G, Sciagrà R, Venditti F, Bellandi B, Vergara R, Migliorini A, Valenti R, Antonucci D. **Time-to-treatment and infarct size in STEMI patients undergoing primary angioplasty.** *Int J Cardiol.* 2013 (e2012); 167 (4):1508-1513
- 136) Maioli M, Zeymer U, van 't Hof AW, Gibson CM, Dudek D, Bellandi F, Noc M, Secco GG, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Huber K, **De Luca G**; EGYPT Cooperation. **Impact of Preprocedural TIMI Flow on Myocardial Perfusion, Distal Embolization and Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated by Primary Angioplasty and Glycoprotein IIb/IIIa Inhibitors.** *J Invasive Cardiol.* 2012; 24: 324-7.
- 137) Secco GG, Bortnik M, Rognoni A, Lupi A, Cavallino C, **De Luca G**, Marino PN.

Stable Ventricular Fibrillation in a Heterotopic Heart Transplant Recipient. Heart Lung Circ 2012; 21: 747-9

- 138) **De Luca G**, Gibson CM, Huber K, Dudek D, Cutlip D, Zeymer U, Gyongyosi M, Bellandi F, Noc M, Arntz HR, Maioli M, Secco GG, Zorman S, Gabriel HM, Emre A, Rakowski T, Van't Hof AW. **Time-related impact of distal embolisation on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation.** EuroIntervention. 2012; 8: 470-6.
- 139) Verdoia M, Pergolini P, Restifo M, Camaro C, Rolla R, Schaffer A, Marino P, Bellomo G, Suryapranata H, **De Luca G**. **PIA¹/PIA² polymorphism does not influence response to GPIIb/IIIa inhibitors in patients undergoing coronary angioplasty** Blood Coagulation Fibrinolysis 2013 (e2012); 24: 411-418
- 140) **De Luca G**, Parodi G, Sciagrà R, Bellandi B, Comito V, Vergara R, Migliorini A, Valenti R, Antoniucci D. **Preinfarction angina does not affect infarct size in STEMI patients undergoing primary angioplasty.** Atherosclerosis. 2013 (e2012); 36(4):1020-5
- 141) **De Luca G**, Parodi G, Sciagrà R, Bellandi B, Verdoia M, Vergara R, Migliorini A, Valenti R, Antoniucci D. **Relation of Gender to Infarct Size in ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Angioplasty.** Am J Cardiol 2013 (e2012); 111(7):936-40
- 142) **De Luca G**, Gibson CM, van't Hof, MD AWJ, Cutlip D, Zeymer U, Noc M, Maioli M, Zorman S, Gabriel HM, Secco GG, Emre A, Dudek D, Rakowski T, Gyongyosi M, Huber K, Bellandi F, MD

Impact of time-to-treatment on myocardial perfusion after primary PCI with Gp IIb-IIIa inhibitors. J

Cardiov Med 2013 (e2012): 14:815-820

- 143) **De Luca G**, Dirksen MT, Spaulding C, Kelbaek H, Schlij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Díaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, Stone GW
Impact of diabetes on long-term outcome after primary angioplasty. Insights from the DESERT cooperation. Diabetes care
2013 (e2012); 36(4):1020-5
- 144) Secco GG, Parisi R, Mirabella F, Fattori R, Genoni G, Agostoni P, **De Luca G**, Marino PN, Lupi A, Rognoni A. **P2Y12 inhibitors: pharmacologic mechanism and clinical relevance.** Cardiovasc Hematol Agents Med Chem. 2013 (e2012); 11: 101-5
- 145) **De Luca G**, Secco GG, Iorio S, Verdoia M, Bellomo G, Marino P. **Short-term effects of aspirin and clopidogrel on mean platelet volume among patients with acute coronary syndromes. A single-center prospective study.** Blood Coagul Fibrinolysis. 2012; 23: 756-9.
- 146) **De Luca G**, Dirksen MT, Spaulding C, Kelbæk H, Schlij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Diaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, Stone GW; DESERT Cooperation. **Meta-Analysis Comparing Efficacy and Safety of First Generation Drug-Eluting Stents to Bare-Metal Stents in Patients With Diabetes Mellitus Undergoing Primary Percutaneous Coronary Intervention.** Am J Cardiol. 2013; 111(9):1295-304
- 147) **De Luca G**, Schaffer A, Wirianta J, Suryapranata H. **Comprehensive meta-analysis of radial vs femoral approach in primary angioplasty for STEMI.** Int J Cardiol. 2013;168(3):2070-81

- 148) Ribichini F, Tomai F, Pesarini G, Zivelonghi C, Rognoni A, **De Luca G**, Boccuzzi G, Presbitero P, Ferrero V, Ghini AS, Marino P, Vassanelli C; the CEREAS-DES Investigators.
Long-term clinical follow-up of the multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES versus BMS alone to Eliminate Restenosis (CEREAS-DES).
Eur Heart J. 2013; 34(23):1740-8
- 149) **De Luca G**, Van't Hof AW, Huber K, Gibson CM, Bellandi F, Arntz HR, Maioli M, Noc M, Zorman S, Secco GG, Zeymer U, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Dudek D.
Impact of advanced age on myocardial perfusion, distal embolization, and mortality patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors.
Heart Vessels. 2013;112(8):1083-6
- 150) Verdoia M, Camaro C, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, **De Luca G**. **Mean platelet volume and the risk of periprocedural myocardial infarction in patients undergoing coronary angioplasty.** Atherosclerosis. 2013;228(1):136-41
- 151) **De Luca G**, Dirksen MT, Spaulding C, Kelbæk H, Schlij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Diaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, Stone GW; DESERT cooperation. **Impact of Age on Long-Term Outcome After Primary Angioplasty With Bare-Metal or Drug-Eluting Stent (From the DESERT Cooperation).** Am J Cardiol. 2013;112(2):181-6
- 152) **De Luca G**, Gibson M, Cutlip D, Huber K, Dudek D, Bellandi F, Noc M, Maioli M, Zorman S, Zeymer U, Secco GG, Mesquita Gabriel H, Emre A, Arntz HR, Rakowski T, Gyongyosi M, Hof AW; EGYPT Cooperation.
Impact of multivessel disease on myocardial perfusion and survival among patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitors. Arch Cardiovasc Dis. 2013;106(3):155-61.

- 153) **De Luca G**, Verdoia M, Casseti E, Schaffer A, Di Giovine G, Bertoni A, Di Vito C, Sampietro S, Aimaretti G, Bellomo G, Marino P, Sinigaglia F; Novara Atherosclerosis Study (NAS) group.
Mean platelet volume is not associated with platelet reactivity and the extent of coronary artery disease in diabetic patients.
Blood CoagulFibrinolysis. 2013;24(6):619-24
- 154) Verdoia M, Barbieri L, Schaffer A, Casseti E, Di Giovine G, Bellomo G, Marino P, Sinigaglia F, **De Luca G**.
Platelet distribution width and the risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention.
J ThrombThrombolysis. 2013; 37(3):345-52
- 155) **De Luca G**, Dirksen MT, Spaulding C, Kelbæk H, Schalijs M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Diaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, Stone GW; for the DESERT cooperation.
Time course, predictors and clinical implications of stent thrombosis following primary angioplasty. Insights from the DESERT cooperation.
ThrombHaemost. 2013;110(4):826-33
- 156) **De Luca G**, Van't Hof AW, Huber K, Gibson CM, Bellandi F, Arntz HR, Maioli M, Noc M, Zorman S, Zeymer U, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Dudek D; EGYPT cooperation.
Impact of Hypertension on Distal Embolization, Myocardial Perfusion, and Mortality in Patients With ST Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty.
Am J Cardiol. 2013; 112(8):1083-6
- 157) Niccoli G, Fracassi F, Cosentino N, Falcioni E, Roberto M, **De Luca G**, Leone AM, Burzotta F, Porto I, Trani C, Severino A, Crea F.
No-Reflow Reversibility: A Study Based on Serial Assessment of Multiple Biomarkers.
J Cardiovasc Transl Res. 2013; 6(5):798-807

- 158) **De Luca G**, Verdoia M, Dirksen MT, Spaulding C, Kelbæk H, Schaliij M, Thuesen L, HoevenBy, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Diaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, Stone GW; DESERT Cooperation. **Gender-related differences in outcome after BMS or DES implantation in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: Insights from the DESERT cooperation.** *Atherosclerosis.* 2013;230(1):12-6.
- 159) Savarese G, Gotto AM Jr, Paolillo S, D'Amore C, Losco T, Musella F, Scala O, Marciano C, Ruggiero D, Marsico F, **De Luca G**, Trimarco B, Perrone-Filardi P. **Benefits Of Statins In Elderly Subjects Without Established Cardiovascular Disease. A Meta-Analysis.** *J Am Coll Cardiol.* 2013;62(22):2090-9
- 160) **De Luca G**, Parodi G, Sciagrà R, Venditti F, Bellandi B, Vergara R, Migliorini A, Valenti R, Antoniucci D. **Preprocedural TIMI flow and infarct size in STEMI undergoing primary angioplasty.** *J Thromb Thrombolysis.* 2014;38(1):81-6
- 161) Schaffer A, Verdoia M, Barbieri L, Aprami TM, Suryapranata H, Marino P, **De Luca G**; on behalf of the Novara Atherosclerosis Study Group (NAS). **High-Density Lipoproteins and Coronary Artery Disease: A Single-Center Cohort Study.** *Angiology.* 2014; 65(8):696-702
- 162) **De Luca G**, Secco GG, Verdoia M, Casseti E, Schaffer A, Coppo L, Marino P; on behalf of the Novara Atherosclerosis Study Group (NAS). **Combination between mean platelet volume and platelet distribution width to predict the prevalence and extent of coronary artery disease: results from a large cohort study.** *Blood Coagul Fibrinolysis.* 2014; 25(1):86-91

- 163) **De Luca G**, Parodi G, Sciagrà R, Bellandi B, Comito V, Vergara R, Migliorini A, Valenti R, Antonucci D.
Impact of hypertension on infarct size in ST elevation myocardial infarction patients undergoing primary angioplasty.
J Hypertens. 2013;31(12):2433-7.
- 164) Verdoia M, Secco GG, Barbieri L, Casetti E, Schaffer A, Sinigaglia F, Marino P, Suryapranata H, **De Luca G**; on behalf of the Novara Atherosclerosis Study Group (NAS).
Platelet HPA-1 a/HPA-1 b polymorphism and the risk of periprocedural myocardial infarction in patients undergoing elective PCI.
Platelets. 2014; 25(5):367-72
- 165) Verdoia M, Barbieri L, Schaffer A, Casetti E, Marino P, Bellomo G, Sinigaglia F, **De Luca G**; on behalf of the Novara Atherosclerosis Study Group (NAS).
Platelet-larger cell ratio and the risk of periprocedural myocardial infarction after percutaneous coronary revascularization.
Heart Vessels. 2015 (e2013); 30(1):20-7
- 166) Verdoia M, Schaffer A, Barbieri L, Casetti E, Piccolo R, Galasso G, Marino P, Sinigaglia F, **De Luca G**.
Benefits from new ADP-antagonists as compared to clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials.
J Cardiovasc Pharmacol. 2014;63(4):339-50
- 167) **De Luca G**, Schaffer A, Verdoia M, Suryapranata H.
Meta-analysis of 14 trials comparing bypass grafting vs drug-eluting stents in diabetic patients with multivessel coronary artery disease. NutrMetab Cardiovasc Dis. 2014;24(4):344-54

- 168) Verdoia M, Schaffer A, Casseti E, Barbieri L, Di Giovine G, Marino P, **De Luca G**; Novara Atherosclerosis Study Group (NAS).
MTHFR polymorphism and risk of periprocedural myocardial infarction after coronary stenting.
NutrMetabCardiovascDis. 2014 (e2013); 24(5):532-7
- 169) Verdoia M, Secco GG, Casseti E, Schaffer A, Barbieri L, Perrone-Filardi P, Marino P, Suryapranata H, Sinigaglia F, **De Luca G**.
Platelet PIA1/PIA2 polymorphism and the risk of periprocedural myocardial infarction in patients with acute coronary syndromes undergoing coronary angioplasty. Blood
Coagul Fibrinolysis. 2014;25(2):107-13.
- 170) **De Luca G**, Parodi G, Sciagrà R, Bellandi B, Comito V, Vergara R, Migliorini A, Valenti R, Antonucci D.
Smoking and infarct size among STEMI patients undergoing primary angioplasty.
Atherosclerosis. 2014;233(1):145-8.
- 171) Verdoia M, Schaffer A, Barbieri L, Casseti E, Nardin M, Bellomo G, Marino P, Sinigaglia F, **De Luca G**; on behalf of the Novara Atherosclerosis Study (NAS) group.
Diabetes, glucose control and mean platelet volume: a single-centre cohort study.
Diabetes Res Clin Pract. 2014;104(2):288-94
- 172) Verdoia M, Casseti E, Schaffer A, Barbieri L, Di Giovine G, Nardin M, Marino P, Sinigaglia F, **De Luca G**; on behalf of the Novara Atherosclerosis Study Group (NAS).
Relationship Between Glycoprotein IIIa Platelet Receptor Gene Polymorphism and Coronary Artery Disease.
Angiology. 2015 (e2014);66(1):79-85

- 173) Verdoia M, Schaffer A, Barbieri L, Cassetti E, Di Giovine G, Marino P, **De Luca G.**
Homocysteine and risk of periprocedural myocardial infarction in patients undergoing coronary stenting.
J Cardiovasc Med (Hagerstown). 2015;16(2):100-5
- 174) **De Luca G**, Secco GG, Cassetti E, Verdoia M, Bellomo G, Marino P; on behalf of the Novara Atherosclerosis Study Group (NAS).
Haemoglobin levels do not correlate with the extent of coronary artery disease: results from a large cohort study.
Coron Artery Dis. 2014;25(6):463-8
- 175) Verdoia M, Barbieri L, Schaffer A, Cassetti E, Nardin M, Bellomo G, Aimaretti G, Marino P, Sinigaglia F, **De Luca G**; on behalf of the Novara Atherosclerosis Study Group (NAS).
Impact of diabetes on uric acid and its relationship with the extent of coronary artery disease and platelet aggregation: A single-centre cohort study.
Metabolism. 2014;63(5):640-6
- 176) **De Luca G**, Wirianta J, Lee JH, Kaiser C, Di Lorenzo E, Suryapranata H.
Sirolimus-eluting versus paclitaxel-eluting stent in primary angioplasty: a pooled patient-level meta-analysis of randomized trials.
J Thromb Thrombolysis. 2014;38(3):355-63
- 177) Parodi G, **De Luca G**, Bellandi B, Comito V, Valenti R, Marcucci R, Carrabba N, Migliorini A, Ramazzotti RN, Gensini GF, Abbate R, Antoniucci D.
Switching from clopidogrel to prasugrel in patients having coronary stent implantation.
J Thromb Thrombolysis. 2014;38(3):395-401

- 178) **De Luca G**, Verdoia M, Schaffer A, Suryapranata H, Parodi G, Antonucci D, Marino P.
Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience.
J Thromb Thrombolysis. 2014;38(3):388-94
- 179) Piccolo R, Galasso G, **De Luca G**, Parodi G, Antonucci D, Esposito G, Trimarco B, Piscione F.
Relationship between changes in platelet reactivity and ischemic events following percutaneous coronary intervention: A meta-regression analysis of 30 randomized trials.
Atherosclerosis. 2014;234(1):176-184.
- 180) **De Luca G**, Dirksen MT, Spaulding C, Kelbæk H, Schlij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, Stone GW.
Drug-eluting stents in patients with anterior STEMI undergoing primary angioplasty: a substudy of the DESERT cooperation.
Clin Res Cardiol. 2014;103(9):685-99
- 181) Barbieri L, Verdoia M, Schaffer A, Nardin M, Marino P, **De Luca G**.
The role of statins in the prevention of contrast induced nephropathy: a meta-analysis of 8 randomized trials.
J Thromb Thrombolysis. 2014;38(4):493-502
- 182) **De Luca G**, Parodi G, Sciagrà R, Bellandi B, Comito V, Vergara R, Migliorini A, Valenti R, Antonucci D.
Impact of multivessel disease on infarct size among STEMI patients undergoing primary angioplasty.
Atherosclerosis. 2014;234(1):244-8.

- 183) Verdoia M, Schaffer A, Cassetti E, Barbieri L, Di Ruocco MV, Perrone-Filardi P, Marino P, **De Luca G**; on behalf of the Novara Atherosclerosis Study Group (NAS).
Glycosylated Hemoglobin and Coronary Artery Disease in Patients Without Diabetes Mellitus.
Am J PrevMed. 2014; 47(1):9-16
- 184) Verdoia M, Schaffer A, Sartori C, Barbieri L, Cassetti E, Marino P, Galasso G, **De Luca G**; The Novara Atherosclerosis Study Group (NAS).
Vitamin D deficiency is independently associated with the extent of coronary artery disease.
Eur J Clin Invest. 2014;44(7):634-42
- 185) Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Marino P, **De Luca G**; Novara Atherosclerosis Study Group (NAS).
Uric acid and risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention.
DiabetesMetab Res Rev. 2014;30(4):297-304
- 186) **De Luca G**, Dirksen MT, Spaulding C, Kelbæk H, Schlij M, Thuesen L, van derHoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Diaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, Stone GW; DESERT cooperation.
Impact of hypertension on clinical outcome in STEMI patients undergoing primary angioplasty with BMS or DES: Insights from the DESERT cooperation.
Int J Cardiol. 2014;175(1):50-4.
- 187) Verdoia M, Barbieri L, Schaffer A, Cassetti E, Di Giovine G, Nardin M, Bellomo G, Marino P, **De Luca G**; on behalf of the Novara Atherosclerosis Study Group (NAS).
Effect of diabetes mellitus on periprocedural myocardial infarction in patients undergoing coronary stent implantation.
Diabetes Metab Res Rev. 2015;31(1):85-92

- 188) Schaffer A, Verdoia M, Cassetti E, Marino P, Suryapranata H, **De Luca G**; on behalf of the Novara Atherosclerosis Study Group (NAS).
Relationship between homocysteine and coronary artery disease. Results from a large prospective cohort study.
Thromb Res. 2014;134(2):288-93.
- 189) Barbieri L, Verdoia M, Schaffer A, Niccoli G, Perrone-Filardi P, Bellomo G, Marino P, Suryapranata H, **De Luca G**.
Elevated Homocysteine and the Risk of Contrast-Induced Nephropathy: A Cohort Study.
Angiology. 2015 (e2014); 66(4):333-8
- 190) **De Luca G**, Dirksen MT, Kelbæk H, Thuesen L, Vink MA, Kaiser C, Chechi T, Spaziani G, Di Lorenzo E, Suryapranata H, Stone GW.
Paclitaxel-eluting versus bare metal stents in primary PCI: a pooled patient-level meta-analysis of randomized trials.
J Thromb Thrombolysis. 2015;39(1):101-12
- 191) Verdoia M, Schaffer A, Barbieri L, Sinigaglia F, Marino P, Suryapranata H, **De Luca G**; Novara Atherosclerosis Study Group (NAS).
Eosinophils count and periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions.
Atherosclerosis. 2014;236(1):169-174.
- 192) Verdoia M, Schaffer A, Cassetti E, Di Giovine G, Marino P, Suryapranata H, **De Luca G**.
Absolute eosinophils count and the extent of coronary artery disease: a single centre cohort study.
J Thromb Thrombolysis. 2015;39(4):459-66

- 193)** Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Carbone G, Lanni F, Pagliuca MR, Stanco G, Rosato G, Suryapranata H, **De Luca G.**
Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents in Patients With ST Elevation Myocardial Infarction: RACES-MI Trial.
JACC Cardiovasc Interv 2014; 7: 849-56.
- 194)** Verdoia M, Cassetti E, Schaffer A, Di Giovine G, **De Luca G.**
Platelet glycoprotein IIIa Leu33Pro gene polymorphism and coronary artery disease: A meta-analysis of cohort studies.
Platelets. 2015 (e2014); 26(6):530-5
- 195)** Barbieri L, Verdoia M, Schaffer A, Cassetti E, Marino P, Suryapranata H, **De Luca G;** Novara Atherosclerosis Study Group (NAS).
Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI.
NutrMetabCardiovascDis. 2015 (e2014); 25(2):181-6
- 196)** Cassese S, **De Luca G,**Ribichini F, Cernigliaro C, Sansa M, Versaci F, Proietti I, Stankovic G, Stojkovic S, Fernandez-Pereira C, Tomai F, Vassanelli C, Antonucci D, Serruys PW, Kastrati A, Rodriguez AE.
ORAlImmunosuppressive therapy to prevent in-Stent rEstenosiS (RAMSES) cooperation: A patient-level meta-analysis of randomized trials.
Atherosclerosis. 2014;237(2):410-7.
- 197)** Barbieri L, Verdoia M, Schaffer A, Cassetti E, Di Giovine G, Marino P, Suryapranata H, **De Luca G.**
Pre-diabetes and the risk of contrast induced nephropathy in patients undergoing coronary angiography or percutaneous intervention.
DiabetesRes Clin Pract. 2014;106(3):458-64

- 198) Verdoia M, Schaffer A, Suryapranata H, **De Luca G**.
Effects of HDL-modifiers on cardiovascular outcomes: A meta-analysis of randomized trials.
NutrMetab Cardiovasc Dis. 2014;237(2):410-7
- 199) **De Luca G**, Parodi G, Sciagrà R, Bellandi B, Vergara R, Migliorini A, Valenti R, Antoniucci D.
Effect of diabetes on scintigraphic infarct size in STEMI patients undergoing primary angioplasty.
Diabetes Metab Res Rev. 2015;31(3):322-8
- 200) Valenti R, Marcucci R, Capodanno D, **De Luca G**, Migliorini A, Gori AM, Parodi G, Giusti B, Carrabba N, Paniccia R, Cantini G, Marrani M, Gensini GF, Abbate R, Antoniucci D.
Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study.
J Thromb Thrombolysis. 2015;40(1):76-82
- 201) **De Luca G**, Suryapranata H.
Recent Advances in Optimal Adjunctive Antithrombotic Therapy in STEMI Patients Undergoing Primary Angioplasty: an Overview.
CurrVascPharmacol. 2015;13(5):594-615
- 202) Secco GG, Parisi R, Mirabella F, Rognoni A, Lupi A, **De Luca G**, Marino PN, Fattori R, Cremonesi A, Castriota F.
Old and New Drugs for Treatment of Stable Angina: New Anti-Anginal Drugs and Coronary Revascularization.
Cardiovasc Hematol Agents Med Chem. 2015; 13(1):21-4

- 203) Verdoia M, Schaffer A, Barbieri L, Bellomo G, Marino P, Sinigaglia F, Suryapranata H, **De Luca G**; on behalf of the Novara Atherosclerosis Study (NAS) group.
Impact of age on mean platelet volume and its relationship with coronary artery disease: A single-centre cohort study.
Exp Gerontol 2015; 62: 32-6
- 204) Suryapranata H, **De Luca G**.
Short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO™ dual-therapy stent: what we plan to learn from REDUCE.
Future Cardiol. 2015;11(1):17-20.
- 205) Verdoia M, Barbieri L, Schaffer A, Cassetti E, Di Giovine G, Nardin M, Bellomo G, Marino P, **De Luca G**; Novara Atherosclerosis Study Group (NAS).
Effect of diabetes mellitus on periprocedural myocardial infarction in patients undergoing coronary stent implantation.
Diabetes Metab Res Rev. 2015;31(1):85-92.
- 206) **De Luca G**, Van't Hof AW, Gibson CM, Cutlip D, Zeymer U, Noc M, Maioli M, Zorman S, Gabriel HM, Emre A, Rakowski T, Gyongyosi M, Huber K, Bellandi F, Dudek D; EGYPT cooperation.
Impact of Time from Symptom Onset to Drug Administration on Outcome in Patients Undergoing Glycoprotein IIb-IIIa Facilitated Primary Angioplasty (from the EGYPT Cooperation).
Am J Cardiol. 2015;115(6):711-5
- 207) Verdoia M, Schaffer A, Barbieri L, Aimaretti G, Marino P, Sinigaglia F, Suryapranata H, **De Luca G**; on behalf of the Novara Atherosclerosis Study Group (NAS).
Impact of diabetes on neutrophil-to-lymphocyte ratio and its relationship to coronary artery disease.
Diabetes Metab. 2015;41(4):304-11

- 208) Schaffer A, Verdoia M, Cassetti E, Barbieri L, Perrone-Filardi P, Marino P, **De Luca G.**
Impact of red blood cells count on the relationship between high density lipoproteins and the prevalence and extent of coronary artery disease.
J Thromb Thrombolysis. 2015;40(1):61-8
- 209) Verdoia M, Schaffer A, Pergolini P, Rolla R, Barbieri L, Bellomo G, Sinigaglia F, Marino P, Suryapranata H, **De Luca G;** on behalf of the Novara Atherosclerosis Study Group (NAS).
Homocysteine levels influence platelet reactivity in coronary artery disease patients treated with acetylsalicylic acid.
J Cardiovasc Pharmacol. 2015;66(1):35-40
- 210) Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Marino P, Suryapranata H, **De Luca G;** of the Novara Atherosclerosis Study Group (NAS).
Glycosylated hemoglobin and the risk of periprocedural myocardial infarction in non-diabetic patients.
J Diabetes Complications 2015; 29: 517-22
- 211) Barbieri L, Verdoia M, Schaffer A, Marino P, Suryapranata H, **De Luca G;** Novara Atherosclerosis Study Group (NAS).
Impact of sex on uric acid levels and its relationship with the extent of coronary artery disease: A single-centre study.
Atherosclerosis 2015; 241: 241-8.
- 212) Verdoia M, Barbieri L, Giovine GD, Marino P, Suryapranata H, **De Luca G;** Novara Atherosclerosis Study Group (NAS).
Neutrophil to Lymphocyte Ratio and the Extent of Coronary Artery Disease: Results From a Large Cohort Study.
Angiology 2016;67: 75-82.
- 213) Barbieri L, Verdoia M, Schaffer A, Marino P, **De Luca G.**
Two catheters for one coronary perforation.
G Ital Cardiol (Rome). 2015;16(2):112-5.